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Significance of this study
What is already known about this subject?
 ► Despite the global dissemination of recommenda-
tions from the available guidelines, current clinical 
practice patterns for patients who initiate glucose- 
lowering agents is not well known. The process 
by which physicians in the Netherlands choose 
glucose- lowering medications to treat patients with 
T2DM is poorly understood.
What are the new findings?
 ► Our findings showed that in the Netherlands, med-
ication treatment in patients with T2DM is main-
ly consistent with the clinical guidelines in the 
Netherlands during the study period.
How might these results change the focus of 
research or clinical practice?
 ► Identifying factors associated with switching would 
help guide clinicians toward a medication treatment 
choice and could also help patients to improve their 
response to treatment.
AbStrAct
Rationale and objectives Different classes of glucose- 
lowering medications are used for patients with type 2 
diabetes mellitus (T2DM) management. It is unclear how 
often these medications are prescribed in clinical practice. 
In this study, we aimed to describe treatment patterns of 
glucose- lowering medications in patients with T2DM in the 
Netherlands.
Methods We studied a cohort of 73 819 patients with 
T2DM, aged ≥45 years with a first prescription for oral 
glucose- lowering medication between 2011 and 2017. 
We used the NControl database with dispensing data 
from 800 pharmacies in the Netherlands. Prevalence of 
each glucose- lowering medication class during 6 years 
after the index date was calculated. Using SQL Server, we 
identified stepwise patterns of medication prescription in 
this population.
Findings During the study period, prevalence of 
biguanides (BIGU) decreased from 95.6% to 80.8% and 
use of sulfonylureas (SU) increased from 27.3% to 42.3%. 
55.2% of all patients only received BIGUs, 19.1% of all 
patients started on BIGUs but switched to BIGU +SU. 
13.5% of patients with T2DM initiated insulins, on average 
532 days (almost 18 months) after the index date.
Conclusions Our findings showed that in the Netherlands, 
medication treatment in patients with T2DM is mainly 
consistent with the clinical guidelines in the Netherlands 
during the study period.
InTRoduCTIon
Type 2 diabetes mellitus (T2DM) is one of 
the most common chronic disorders, with 
a worldwide estimated prevalence of 9% 
in 2014.1 According to the International 
Diabetes Federation, among the adult (age 
20–79 years) population of 661 million in 
Europe in 2017, the prevalence of T2DM has 
been estimated at 6.9% (ranging between 
5.5% and 9.9%).2 In the Netherlands, in 
2013, this percentage was 5.5% (measured 
among a study population of 8 million inhab-
itants; roughly half of the total population).3 
T2DM has been related to increased risk of 
comorbidities, for example, cardiovascular 
disease, with 5 million deaths annually.1
Different classes of glucose- lowering medi-
cations with different efficacy, side effects and 
tolerability have been approved for T2DM 
management.4 According to the Dutch clin-
ical guidelines and the American Diabetes 
Association (ADA), until 2018 and during the 
study period, a medication treatment algo-
rithm in T2DM based on diabetes progression 
was used. Treatment begins with biguanides 
(BIGUs) such as metformin, adds a sulfony-
lurea (SU) when BIGUs do not adequately 
control hyperglycemia, then adds basal insu-
lins, and eventually moves on to more inten-
sive pharmacotherapy with insulins.5–7
Despite the global dissemination of recom-
mendations from the available guidelines, 
current clinical practice patterns for patients 
who initiate glucose- lowering agents is not 
well known. The process by which physicians 
in the Netherlands choose glucose- lowering 
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medications to treat patients with T2DM is poorly 
understood.
We, therefore, among a population with T2DM in 
the Netherlands aimed to investigate the prevalence of 
glucose- lowering medications dispensed by community 
pharmacies, and to show the most frequent sequential 
patterns in the treatment of T2DM, during 6 years after 
the onset of diabetes. We further assessed if age or gender 
affected treatment patterns.
MeTHods
Research design and study setting
In a longitudinal retrospective follow- up study, we used 
data obtained between 2012 and 2017 from the NCon-
trol database that includes dispensing data from 800 
pharmacies (approximately 6 million patients) located 
in different regions of the Netherlands. This database 
has been a source for multiple studies8 9 and includes 
information on patient demographics (age and gender) 
and drug dispensing records from mainly community 
pharmacies and, to a lesser extent, outpatient pharma-
cies located in the hospitals. Detailed information on the 
dispensed drug, type of prescriber, dispensing dates, the 
amount dispensed, and the written dose instructions are 
also available in this database.
Glucose-lowering medications use
As shown in online supplementary table S1, glucose- 
lowering medications were coded according to the 
Anatomical Therapeutic Chemical (ATC) codes: A10A 
(insulin preparations) and A10B (oral glucose- lowering 
medication).10 Exposure to glucose- lowering medications 
was defined as a dispensing record of a prescription for the 
medications categorized into the following groups (ATC 
code between brackets): (1) BIGUs (A10BA); (2) SU 
(A10BB); (3) alpha- glucosidase inhibitors (A10BF); (4) 
thiazolidinediones (A10BG); (5) dipeptidyl peptidase 4 
(DPP-4) inhibitors (A10BH); (6) glucagon- like peptide-1 
(GLP-1) analogues (A10BJ); (7) sodium- glucose co- trans-
porter 2 (SGLT2) inhibitors (A10BK); and (8) insulins 
(A10A) (online supplementary table S1).
defining treatments, switches and add-ons
We define treatments based on the medication that the 
patient has in his possession at any given point in time. 
We use the daily defined dose as defined by the WHO to 
calculate the number of days for which any of the above 
groups of medication is dispensed.10 We report a switch 
when the medication group in the patients possession 
changes from one group to one or more other groups. 
We report an add- on if a new group of medication is 
dispensed, while the previously dispensed medication is 
still in the patient’s possession. We add a buffer of 30 days 
to each dispension to correct for medication possession 
gaps that may occur due to non- adherence. This has the 
additional wanted effect that a treatment that is made up 
from multiple medications that are dispensed asynchro-
nously, but shortly after each other, will be reported as 
one unchanged treatment, rather than many recurring 
switches back and forth between the same medications.
study population
All patients who filled at least two oral glucose- lowering 
medication prescriptions (A10B) during the follow- up 
(from 2012 to 2017) were considered to have T2DM. 
The date of first ever oral glucose- lowering medication 
dispensing was selected as the cohort entry date (index 
date). Patients were eligible for inclusion in the study if 
they had at least 12- month follow- up, calculated as the 
number of days between their first and last prescription 
of diabetes medication. We only included patients that 
were newly diagnosed during our study period. These 
are patients that received no diabetes medication during 
the 12 months before the index date. Two approaches 
were used to minimize the risk of possible type 1 diabetes 
misclassification: individuals who were initially treated 
with insulin as monotherapy were excluded, and only 
patients aged 45 years and older at which age the risk of 
developing T2DM increases were selected.11 12
statistical analysis
Descriptive statistics were used to summarize the char-
acteristics of patients with T2DM. Overall and annual 
prevalence of each class of glucose- lowering medications 
were calculated in the period 6 years after the index date. 
Characteristics of patients who were treated with insu-
lins during follow- up were further studied as well. We 
used a χ2 statistical test to test if the differences between 
different age groups (45–55, 56–65 and ≥66 years) and 
gender were statistically significant.
Using SQL Server Management Studio, treatment 
steps were studied. We report overviews of the most 
frequent two- step combinations. A two- step combination 
is a change from one treatment to another. (In our anal-
ysis, Start and End of observation are considered treat-
ment steps.) In subgroup analyses, treatment steps were 
compared between genders.
data availability
The data that support the findings of this study are avail-
able from NControl B.V. but restrictions apply to the 
availability of these data, which are not publicly available. 
Data are, however, available from the authors on reason-
able request and with permission of NControl B.V.
Resource availability
No applicable resources were generated or analyzed 
during the current study.
ResulTs
Baseline characteristics
A total of 73 819 eligible patients with T2DM aged ≥45 
years at the index date were identified (table 1). The 
mean age at the index date was 65.0±11.2 years and the 
majority of patients included in this study were men 
(54.9%). At the index date, 46.8% of patients were aged 
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Table 1 Baseline characteristics of patients with T2DM, 
and patients who received insulin
T2DM cohort 
(n=73 819)
Patients with 
T2DM with 
insulin during 
follow- up 
(n=9969)
Gender,
n (%)
Male 40 521 (54.9) 5277 (52.9)
Female 33 298 (45.1) 4692 (47.1)
  
Age at first 
glucose- lowering 
medication use 
(index date)
Age at first 
insulin use
Age,
n (%)
45–55 y 17 444 (23.6) 2640 (26.5)
56–65 y 21 816 (29.6) 2800 (28.1)
≥66 y 34 559 (46.8) 4529 (45.4)
T2DM, type 2 diabetes mellitus.
Figure 1 Prevalence of different classes of diabetes medications during follow- up.
≥66 years. The average follow- up period for all patients 
was 1188 days, calculated as the number of days between 
their first and last diabetes prescription.
As shown in figure 1, the overall prevalence of BIGUs 
and SUs were 96.3% and 41.7%, respectively. Most 
patients start on BIGU, but during the follow- up, there 
was a slight decrease in the use of BIGUs (from 95.6% to 
80.8%). At the same time, an increase in the use of SUs 
and DPP-4 inhibitors was observed, from 27.3% to 42.3% 
and from 3.7% to 7.9%, respectively (figure 1). Overall, 
the prevalence of SGLT2 inhibitors (1.3%) and GLP-1 
analogues (1.2%) was low, but they showed an increase 
in the use during the 6 years after index date in this 
population. No significant differences in the prevalence 
of oral glucose- lowering medications were seen between 
patients in different age groups and gender.
A total of 9969 (13.5%) patients with T2DM used 
insulin at some point during follow- up. Patients in the 
age group of 45–55 years at the index date were more 
likely to initiate treatment with insulin during follow- up 
(p<0.001). Most of the patients who used insulin 
were men (52.9% men vs 47.1% women, even though 
women only represent 45.1% of the study population; p 
value<0.001) (table 1). The average time of switching to 
insulin therapy in this population was roughly 18 months 
after the index date.
Figure 2 shows the most frequently observed treat-
ment steps for each drug class during the follow- up. The 
majority of patients with T2DM (55.2%) only received 
BIGUs and 19.1% of all patients started BIGUs and then 
added SU (treatment BIGU+SU). Switching from BIGU 
to SU happened in 8.2% of this population (figure 2). In 
23.8% of all patients, the last measured treatment during 
follow- up was BIGU+SU. According to the standards, 
this treatment is the first step after BIGU, meaning that 
patients have not progressed further in the treatment 
path, at least not during our study period. In a small 
percentage of patients, the last measured treatment 
during the follow- up consisted of insulins (0.8%) as 
monotherapy, insulins combined with BIGUs (4.6%), or 
insulins with BIGU+SU (4.9%).
The most important different treatment paths are 
shown in figure 2. The average time interval between 
4300.7802.430. Protected by copyright.
 o
n
 February 5, 2020 at Erasm
us M
edical / X51
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000767 on 7 January 2020. Downloaded from 
4 BMJ Open Diab Res Care 2020;8:e000767. doi:10.1136/bmjdrc-2019-000767
Epidemiology/Health Services Research
Figure 2 T2DM treatment paths, all patients. Numbers next 
to the arrows represent the percentage of patients taking 
the represented step in the treatment path. Numbers below 
treatments represent the average number of days on this 
treatment. T2DM, type 2 diabetes mellitus.
Figure 3 T2DM treatment paths by gender. Numbers next to the arrows represent the percentage of patients taking the 
represented step in the treatment path. Numbers below treatments represent the average number of days on this treatment. 
T2DM, type 2 diabetes mellitus.
switching from mono therapy with BIGUs to combina-
tion therapy was roughly 14 months after the index date. 
Figure 3 A,B shows the treatment paths separately in men 
and women, with no clinically significant differences. 
We do find that the switch to or add- on of insulin takes 
place relatively quickly compared with other medication 
classes. This happens across age categories and genders 
(table 2).
dIsCussIon
To the best of our knowledge, this study is the first large- 
scale study (n=73 819 patients with T2DM) to investigate 
treatment patterns in patients with diabetes in the Neth-
erlands. Over the study period, most patients received 
BIGUs (96.3%) followed by SUs (41.7%). Only a very 
small proportion of patients with T2DM used SGLT2 
inhibitors (1.3%) and GLP-1 analogues (1.2%) over the 
study period. In a total of 13.5% of this population, insu-
lins were initiated and added to other glucose- lowering 
medications, which may represent progression to a more 
severe form of T2DM where insulin is indicated.
According to the Netherlands standard for General 
Practitioners, by the Nederlands Huisartsen Genootschap 
(Netherlands General Practitioners Society) (NHG) 
and the consensus statement from the ADA and the 
European Association for the Study of Diabetes, BIGUs 
such as metformin are recommended as initial therapy 
in patients with T2DM.5–7 Intensive treatment with 
metformin appeared to reduce the risk of diabetes- 
associated complications and all- cause mortality.13 
Furthermore, according to the results of the UK Prospec-
tive Diabetes Study, metformin is recommended as the 
first- line therapy in patients with T2DM.13 In line with 
most previous studies and according to the guidelines 
in the Netherlands and ADA recommendations, our 
study showed that medication treatment was initiated 
with metformin in 95.6% of patients with T2DM.6 14 One 
exception is a study performed by Berkowitz et al, in the 
USA, which reported that only 57.8% of patients with 
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Table 2 Average days on biguanides before changing treatment
Switch to All patients Males Females 45–55 56–65 66+
BIGU+DPP-4- i 364 365 361 357 384 349
BIGU+INS 203 192 218 183 188 221
BIGU+SU 481 486 474 488 503 452
INS 248 274 222 224 225 270
SU 412 438 387 428 444 384
BIGU, biguanides; DPP, dipeptidyl peptidase; INS, insulin; SU, sulfonylurea.
T2DM started treatment with metformin. Interestingly, 
in the study by Berkowitz et al, researchers found that 
initial use of metformin was associated with a lower risk of 
subsequent treatment intensification compared with the 
other oral glucose- lowering medications.15 In our study, 
the high percentage of metformin selected as the first- 
line medication treatment reflects physicians’ adherence 
to the guidelines.
SUs such as gliclazide are classified as the second most 
frequent medication used in patients with T2DM. When 
BIGUs are contraindicated for instance in patients with 
renal impairment or with advanced heart failure, SUs 
are initiated. Our finding here is also consistent with the 
current guidelines.6
In our study, we observed a steady decline in the use 
of BIGUs during follow- up, which may be explained, 
at least partly, by launching the new generation 
of glucose- lowering medications. For patients on 
BIGUs or SUs who do not achieve glycemic targets, 
GLP-1 receptor agonists and SGLT2 inhibitors are 
suggested.16 Both medications have been shown 
effective with minimal risk of hypoglycemia.16 In 
our study, despite the low prevalence rates of GLP-1 
receptor agonists and SGLT2 inhibitors, there was an 
increasing trend over the study period.
It has been reported that compared with women, 
European men are diagnosed with T2DM at an earlier 
age.17 Diversities in factors such as lifestyle, environ-
mental and genetic factors impact significant differ-
ences between men and women in clinical presentation, 
diabetes progression and unfavorable diabetes- associated 
complications.18 Conventionally, in patients with T2DM, 
choice of medication treatment, monotherapy, combina-
tion therapy or add- on insulin therapy, reflects a balance 
between several different factors such as efficacy to 
achieve glycemic control, contraindication due to adverse 
drug reactions, risk of hypoglycemia, patient preference, 
the effects on body weight and cost. Although changes in 
treatment patterns of glucose- lowering medications over 
time might be influenced by these factors, we consider it 
good practice that physicians in the Netherlands mostly 
follow the clinical guidelines.
Our study shows that many treatment paths for treating 
T2DM exist. Patients may move back and forth through 
this path or may take a treatment path that is not in line 
with the standards. Medication changes may be due to 
the progression of the disease, however, may also be 
caused by the generic approach to treating T2DM as 
suggested in the guidelines may work for most, but not all 
patients. Research that addresses phenotypes, personal 
and environmental factors in patients may help to target 
the right treatment to the right patient in an early stage. 
Studies using novel technologies in the field of ‘omics or 
other big data approaches may provide physicians with 
new means to diagnose and to treat patients with diabetes 
effectively. There have been promising results identifying 
metabolomic biomarkers to enhance personalized treat-
ment in T2DM.19
The main strength of this study is that we used 
the NControl database, a large population- based 
dataset which provides accurate data on medications 
dispensing. We included 73 819 adults aged ≥45 years 
who were newly started on oral glucose- lowering medi-
cations; therefore, there was little chance of misclas-
sified type 1 diabetes. We developed a technique that 
allows us to mine the most frequent patterns. The 
strength of using this technique is that we know and 
can describe exactly which steps were taken, which 
may not be as easy when using ‘black box’ algorithms 
provided by in- market (open source) software pack-
ages. However, there are some limitations in our 
study that should be acknowledged. Our analysis was 
performed on pharmacy- based data. Not all patients 
have an equal follow- up period. Patients that started 
using T2DM medication in the later years of our study 
period, have a shorter follow- up period than patients 
that entered the study in the earlier years, and this may 
influence some of the results, especially for calcula-
tions related to average number of days on treatment 
or before switch. We know which prescriptions have 
been filled, but we cannot know with certainty which 
medications have been taken. Also, some patients 
may have filled part of their prescriptions in pharma-
cies outside our NControl universe. However, we do 
know from other research that patients in the Neth-
erlands are registered with a single community phar-
macy, and that records with regard to prescription 
drugs are virtually complete.20 Our database contains 
no detailed clinical information. There is a possibility 
that some patients with type 1 diabetes may have been 
misclassified as patients with type 2 diabetes. Also, if 
was not possible for us to distinguish patients that may 
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suffer from Latent Autoimmune Diabetes in Adults 
(LADA), which occurs among 9.7% of patients with 
adult- onset diabetes, as reported in Action LADA.21 
Metformin is prescribed mainly for the treatment of 
T2DM, but may also be prescribed for patients with 
obesity and pre- diabetes in women of reproductive 
age, mostly below the age of 45 years.22 23 On the 
other hand, since we used pharmacy prescription 
data, we were not able to assess factors associated 
with switching; merely age and gender were available. 
Identifying factors associated with switching would 
help guide clinicians toward a medication treatment 
choice and could also help patients to improve their 
response to treatment. We were able to follow eligible 
patients with T2DM during a period of 6 years. It is 
to be expected that due to the progressive nature of 
the disease and the trend reported in this study, the 
percentage of patients using insulin at the end of 
follow- up would have been greater if we would be able 
to extend this period to longer follow- up.24 25
In summary, our study showed different treatment 
steps for patients initiating oral glucose- lowering medica-
tions in the Netherlands. The apparent complex patient 
journey in treatment choice is mainly consistent with 
the current clinical guidelines. Our study suggests that 
the sequential pattern mining can give a clear overview 
of the most frequent steps in the treatment journey of 
patients diagnosed with T2DM, that would otherwise be 
too complex to describe.
ethical approval
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